Diagnosis of Eosinophilic Gastritis
Eosinophilic gastritis is diagnosed through endoscopy with gastric biopsies demonstrating ≥30 eosinophils per high-power field (or clustered/sheet-like distribution with epithelial infiltration), combined with compatible gastrointestinal symptoms, after excluding secondary causes of eosinophilia.
Diagnostic Algorithm
Step 1: Clinical Suspicion
Suspect eosinophilic gastritis in patients presenting with:
- Abdominal pain, nausea, vomiting, early satiety
- Anorexia or failure to thrive (children)
- Symptoms refractory to standard therapy
- History of atopic conditions (asthma, food allergies, eczema)
Important caveat: Unlike eosinophilic esophagitis where dysphagia predominates, gastric involvement presents with more non-specific symptoms 1.
Step 2: Endoscopic Evaluation
Perform esophagogastroduodenoscopy (EGD) with targeted biopsies:
Biopsy protocol for gastric involvement:
- Obtain multiple biopsies from both antrum and body of stomach 1
- Take at least 5-6 biopsies from different gastric sites to account for patchy distribution
- Target areas of visible abnormality (nodularity, erythema, erosions) if present 2
Endoscopic findings (though often non-specific):
- Gastric nodularity
- Erythema
- Erosions
- Normal-appearing mucosa (does not exclude diagnosis) 1
Step 3: Histopathologic Criteria
Diagnostic threshold:
- ≥30 eosinophils per high-power field in gastric mucosa is commonly used, though no universally standardized cutoff exists 1
- Alternative diagnostic features include eosinophils in clustered or sheet-like distribution with epithelial infiltration 3
Key histologic features supporting diagnosis 3:
- Eosinophilic infiltration of epithelium (RR=1.661)
- Eosinophilic infiltration of muscularis mucosae (RR=1.818)
- Eosinophil microabscesses
- Eosinophil degranulation
Less common features:
- Neutrophilic epithelial infiltration
- Edema
- Background lymphoplasmacytosis
Step 4: Exclude Secondary Causes
Must rule out:
- Parasitic infections (stool studies, serologies)
- Helicobacter pylori infection (testing mandatory) 4
- Inflammatory bowel disease (Crohn's disease)
- Connective tissue disorders
- Drug hypersensitivity reactions
- Hypereosinophilic syndrome (peripheral eosinophilia >1,500/μL with organ involvement)
- Malignancy
Consider duodenal biopsies only if:
- Symptoms suggest small bowel involvement
- Endoscopic abnormalities in duodenum
- Need to exclude celiac disease or other enteropathies 5, 4
The yield of routine duodenal biopsies in isolated gastric disease is extremely low (0.6% for celiac disease) and does not alter management in most cases 4.
Step 5: Molecular and Biomarker Confirmation (Emerging)
Advanced diagnostic tools (research/specialized centers) 1:
- EG Diagnostic Panel (EGDP18): 18-gene gastric transcript panel (AUC ≥0.95)
- Blood biomarkers: Elevated eotaxin-3, TARC, IL-5, TSLP levels
- Plasma eotaxin-3 strongly correlates with gastric CCL26 expression (r=0.81)
These platforms distinguish active disease from controls and correlate with histologic severity, though not yet standard of care.
Critical Pitfalls to Avoid
- Inadequate biopsy sampling: Eosinophilic infiltration is patchy; insufficient biopsies miss diagnosis
- Confusing with H. pylori gastritis: Always test and treat H. pylori first, as it can cause gastric eosinophilia 4
- Overlooking systemic eosinophilia: Check complete blood count to exclude hypereosinophilic syndrome
- Assuming normal endoscopy excludes disease: Mucosa may appear normal in up to 40% of cases
- Not obtaining antrum AND body biopsies: Disease distribution varies; both sites must be sampled 1
Nuances in Evidence
The diagnostic criteria for eosinophilic gastritis are less standardized than for eosinophilic esophagitis. While EoE has clear consensus guidelines with ≥15 eosinophils/hpf threshold 6, 7, gastric involvement lacks universal agreement on eosinophil counts. The most robust recent study suggests ≥30 eos/hpf or characteristic distribution patterns 3, 1.
Correlation between histology and symptoms is imperfect 1, necessitating endoscopic reassessment after treatment initiation rather than relying on symptom improvement alone—a principle borrowed from EoE management 6.
The 2024 ESPGHAN/NASPGHAN guidelines emphasize that non-EoE eosinophilic gastrointestinal disorders remain diagnosis of exclusion requiring both clinical symptoms AND histologic findings after ruling out secondary causes 5.